Methylene Chloride

Methylene Chloride

SCHEMBL627718

ClCCl.[Ca+2].[H-].[H-]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Methylene Chloride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200297724-A1 COVALENT INHIBITORS OF CDK-7 NEWAVE PHARMACEUTICAL INC. 2020-09-24 US disclosed
US-10456397-B2 Covalent inhibitors of CDK-7 NEWAVE PHARMACEUTICAL INC. (US) 2019-10-29 US disclosed
US-20190151316-A1 COVALENT INHIBITORS OF CDK-7 NEWAVE PHARMACEUTICAL LLC 2019-05-23 US disclosed
US-10195200-B2 Covalent inhibitors of CDK-7 NEWAVE PHARMACEUTICAL INC. (US) 2019-02-05 US disclosed
US-20180008604-A1 COVALENT INHIBITORS OF CDK-7 NEWAVE PHARMACEUTICAL LLC 2018-01-11 US disclosed
WO-2016149031-A1 COVALENT INHIBITORS OF CDK-7 NEWAVE PHARMACEUTICAL LLC (US) 2016-09-22 WO disclosed
EP-1814852-B1 HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS CATALYST BIOSCIENCES INC (US) 2016-01-20 EP disclosed
US-20150313883-A1 HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS TARGACEPT INC (US) 2015-11-05 US disclosed
US-9107915-B2 Hydroxybenzoate salts of metanicotine compounds TARGACEPT, INC. (US) 2015-08-18 US disclosed
US-20140288132-A1 HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS TARGACEPT INC (US) 2014-09-25 US disclosed
EP-0689546-A1 MACROCYCLIC CARBAMATE IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1996-01-03 EP disclosed
EP-0688217-A1 HETEROCYCLE-CONTAINING MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1995-12-27 EP disclosed
WO-1994021643-A1 MACROCYCLIC CARBAMATE IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1994-09-29 WO disclosed
WO-1994021258-A1 HETEROCYCLE-CONTAINING MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1994-09-29 WO disclosed
WO-1994021644-A1 THIO-HETEROCYCLIC MACROLACTAM IMMUNOMODULATORS ABBOTT LABORATORIES (US) 1994-09-29 WO disclosed
US-5247090-A Tricyclic [6,6,5]-fused oxazolidinone antibacterial agents THE UPJOHN COMPANY (US) 1993-09-21 US disclosed
US-5231188-A Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents THE UPJOHN COMPANY (US) 1993-07-27 US disclosed
EP-0500686-A1 TRICYCLIC 6,5,5]/ 6,6,5]-FUSED OXAZOLIDINONE ANTIBACTERIAL AGENTS. UPJOHN CO (US) 1992-09-02 EP disclosed
WO-1991007409-A1 TRICYCLIC [6,5,5]/[6,6,5]-FUSED OXAZOLIDINONE ANTIBACTERIAL AGENTS THE UPJOHN COMPANY (US) 1991-05-30 WO disclosed
US-4702864-A ANTIINFLAMMATORY AGENTS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-10-27 US disclosed